Statin Use Is Not Associated With Presence of and Severity of Nonalcoholic Fatty Liver Disease

Archives of Medical Research

Volumn 45, Issue 1, 2014, Pages 52-57

  Oni, Ebenezer T ^a   Sinha, Pragya ^a   Karim, Adil ^a   Martin, Seth S ^b   Blaha, Michael J ^b   Agatston, Arthur S ^a,c   Blumenthal, Roger S ^b   Meneghelo, Romeu S ^d   Conceiçao, Raquel D ^d   Santos, Raul D ^e   Nasir, Khurram ^a,b,c,f  

^a Baptist Health South Florida   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^d HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Fatty Liver Index; FIB 4 index; Fibrosis; NAFLD; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CLINICAL EXAMINATION; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG USE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LABORATORY TEST; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION;

FATTY LIVER INDEX; FIB-4 INDEX; FIBROSIS; NAFLD; STATINS;

ADULT; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER CIRRHOSIS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84892546104     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2013.12.003     Document Type: Article

References (39)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
2. Eidelman R.S., Lamas G.A., Hennekens C.H. The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease. Arch Intern Med 2002, 162:2033-2036.
3. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005, 41:690-695.
4. Nseir W., Mahamid M. Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review. Curr Atheroscler Rep 2013, 15:305.
5. Nseir W., Shalata A., Marmor A., et al. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci 2011, 56:3439-3449.
6. Tandra S., Vuppalanchi R. Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med 2009, 11:272-278.
7. Adams L.A., Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005, 22:1129-1133.
8. McCullough A.J. Pathophysiology of nonalcoholic steatohepatitis. JClin Gastroenterol 2006, 40(suppl 1):S17-S29.
9. Marchesini G., Marzocchi R., Agostini F., et al. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005, 16:421-427.
10. Neuschwander-Tetri B.A. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci 2005, 330:326-335.
11. Bhatia L.S., Curzen N.P., Byrne C.D. Nonalcoholic fatty liver disease and vascular risk. Curr Opin Cardiol 2012, 27:420-428.
12. Bhatia L.S., Curzen N.P., Calder P.C., et al. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. Eur Heart J 2012, 33:1190-1200.
13. Fraser A., Harris R., Sattar N., et al. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 2007, 27:2729-2735.
14. Charles E.C., Olson K.L., Sandhoff B.G., et al. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med 2005, 118:618-624.
15. Nseir W., Mograbi J., Ghali M. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Dig Dis Sci 2012, 57:1773-1781.
16. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
17. Bader T. Liver tests are irrelevant when prescribing statins. Lancet 2010, 376:1882-1883.
18. Cohen D.E., Anania F.A., Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006, 97:77C-81C.
19. Perloff D., Grim C., Flack J., et al. Human blood pressure determination by sphygmomanometry. Circulation 1993, 88:2460-2470.
20. Cappellari M., Bovi P., Moretto G., et al. The THRombolysis and STatins (THRaST) study. Neurology 2013, 80:655-661.
21. Bellentani S., Saccoccio G., Masutti F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000, 132:112-117.
22. Sumida Y., Yoneda M., Hyogo H., et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol 2012, 12:2.
23. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
24. Ndumele C.E., Nasir K., Conceicao R.D., et al. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol 2011, 31:1927-1932.
25. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
26. Shah R.V., Goldfine A.B. Statins and risk of new-onset diabetes mellitus. Circulation 2012, 126:e282-e284.
27. Minder C.M., Blumenthal R.S., Blaha M.J. Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks. Curr Opin Cardiol 2013, 28:554-560.
28. Musso G., Cassader M., Gambino R. Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update. Curr Opin Lipidol 2011, 22:489-496.
29. Gomez-Dominguez E., Gisbert J.P., Moreno-Monteagudo J.A., et al. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006, 23:1643-1647.
30. Nelson A., Torres D.M., Morgan A.E., et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol 2009, 43:990-994.
31. Athyros V.G., Tziomalos K., Gossios T.D., et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010, 376:1916-1922.
32. Foster T., Budoff M.J., Saab S., et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011, 106:71-77.
33. Abel T., Feher J., Dinya E., et al. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med Sci Monit 2009, 15:MS6-11.
34. Mihaila R.G., Nedelcu L., Fratila O., et al. Effects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitis. Hepatogastroenterology 2009, 56:1117-1121.
35. Rallidis L.S., Drakoulis C.K., Parasi A.S. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004, 174:193-196.
36. Hyogo H., Ikegami T., Tokushige K., et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatol Res 2011, 41:1057-1065.
37. Antonopoulos S., Mikros S., Mylonopoulou M., et al. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006, 184:233-234.
38. Saadeh S., Younossi Z.M., Remer E.M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002, 123:745-750.
39. Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol 2010, 105:978-980.